General anesthesia and opioids — Competitive Intelligence Brief

General anesthesia and opioids (General anesthesia and opioids) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic combination. Area: Anesthesiology.

phase 3 General anesthetic combination Anesthesiology Small molecule

Target snapshot

General anesthesia and opioids (General anesthesia and opioids) — The Cleveland Clinic. This is a combination approach using general anesthetic agents alongside opioid medications to induce and maintain unconsciousness and analgesia during surgical procedures.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
General anesthesia and opioids TARGET	General anesthesia and opioids	The Cleveland Clinic	phase 3	General anesthetic combination
propofol，remifentanil，cis atracurium	propofol，remifentanil，cis atracurium	Tang-Du Hospital	marketed	General anesthetic combination (GABA agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Ketofol as induction agent	Ketofol as induction agent	Fayoum University Hospital	marketed	General anesthetic combination	NMDA receptor antagonist (ketamine) and GABA-A receptor agonist (propofol)
Remifentanil, propofol and citanest	Remifentanil, propofol and citanest	University of Aarhus	marketed	General anesthetic combination	Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)
Remifentanil, Dexmedetomidine, and Desflurane	Remifentanil, Dexmedetomidine, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)
Remifentanil, Propofol, and Desflurane	Remifentanil, Propofol, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
Sevoflurane+Propofol	Sevoflurane+Propofol	Huazhong University of Science and Technology	marketed	General anesthetic combination	GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic combination class)

1. The Cooper Health System · 2 drugs in this class
2. Fayoum University Hospital · 1 drug in this class
3. Huazhong University of Science and Technology · 1 drug in this class
4. Memorial Sloan Kettering Cancer Center · 1 drug in this class
5. The Cleveland Clinic · 1 drug in this class
6. University of Aarhus · 1 drug in this class